Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?

Q2 Agricultural and Biological Sciences

Current Research in Pharmacology and Drug Discovery Pub Date : 2022-01-01 DOI:10.1016/j.crphar.2022.100097

Raja Atreya , Christian Bojarski , Anja A. Kühl , Zlatko Trajanoski , Markus F. Neurath , Britta Siegmund

{"title":"Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?","authors":"Raja Atreya , Christian Bojarski , Anja A. Kühl , Zlatko Trajanoski , Markus F. Neurath , Britta Siegmund","doi":"10.1016/j.crphar.2022.100097","DOIUrl":null,"url":null,"abstract":"<div><p>Within the IBD entity of Crohn's disease, there is currently no differentiation between ileal and colonic manifestation for recruitment of patients in clinical trials, well-powered analysis of study results or therapeutic decisions in daily clinical practice. However, there is accumulating evidence from epidemiological, genetic, microbial, immunological, and clinical characteristics that clearly indicate that ileal Crohn's disease represents a distinct disease entity, which differentiates itself from colonic Crohn's disease. This is also reflected by lower efficacy of targeted therapies in isolated ileal compared to colonic Crohn's disease. The distinct site-specific mechanisms that drive heightened non-response in ileal disease need to be analysed in-depth in the future, to enable optimized therapy in the individual Crohn's disease patient.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"3 ","pages":"Article 100097"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590257122000177/pdfft?md5=fc0aab03baba50b560c0c6a17e894e3a&pid=1-s2.0-S2590257122000177-main.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Pharmacology and Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590257122000177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}

引用次数: 6

Abstract

Within the IBD entity of Crohn's disease, there is currently no differentiation between ileal and colonic manifestation for recruitment of patients in clinical trials, well-powered analysis of study results or therapeutic decisions in daily clinical practice. However, there is accumulating evidence from epidemiological, genetic, microbial, immunological, and clinical characteristics that clearly indicate that ileal Crohn's disease represents a distinct disease entity, which differentiates itself from colonic Crohn's disease. This is also reflected by lower efficacy of targeted therapies in isolated ileal compared to colonic Crohn's disease. The distinct site-specific mechanisms that drive heightened non-response in ileal disease need to be analysed in-depth in the future, to enable optimized therapy in the individual Crohn's disease patient.

查看原文本刊更多论文

回肠和结肠克罗恩病:部位对治疗效果有影响吗?

在克罗恩病的IBD实体中，目前在临床试验中招募患者、对研究结果进行有力分析或在日常临床实践中做出治疗决策时，还没有区分回肠和结肠的表现。然而，越来越多的流行病学、遗传学、微生物学、免疫学和临床特征的证据清楚地表明回肠克罗恩病是一种不同于结肠克罗恩病的疾病实体。与结肠克罗恩病相比，孤立回肠靶向治疗的疗效较低也反映了这一点。未来需要深入分析导致回肠疾病无反应加剧的不同部位特异性机制，以便对克罗恩病患者个体进行优化治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊